Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers.

Trial Profile

A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs PBT 434 (Primary)
  • Indications Brain cancer; Neurodegenerative disorders; Parkinson's disease
  • Focus Adverse reactions; First in man
  • Acronyms PBT434-101
  • Sponsors Prana Biotechnology
  • Most Recent Events

    • 31 Jan 2019 According to a Prana Biotechnology media release, the company expects to complete the trial this year.
    • 18 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 12 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top